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Background
Cardiac magnetic resonance (CMR) T1 mapping has
been used to characterize myocardial diffuse fibrosis.
The aim of this study is to determine the reproducibility
and sample size of CMR fibrosis measurements for use
in clinical trials.
Methods
A modified Look-Locker with inversion recovery
(MOLLI) sequence was used to determine myocardial
T1 values pre-, and 12 and 25 min post-administration
of a gadolinium-based contrast agent at 3 Tesla. For 24
healthy subjects (8 men; 29±6 years), two separate scans
were obtained a) with a bolus of 0.15 mmol/kg of gado-
pentate dimeglumine and b) 0.1 mmol/kg of gadobenate
dimeglumine, respectively, with averaged of 51±34 days
between two scans. Separately, 25 heart failure subjects
(12 men; 63±14 years), were evaluated after a bolus of
0.15mmol/kg of gadopentate dimeglumine. Myocardial
partition coefficient (l) was calculated according to
(ΔR1myocardium/ΔR1blood), and ECV was derived
from l by adjusting (1-hematocrit).
Results
Mean ECV and l were both significantly higher in HF
subjects than healthy (ECV: 0.287±0.034 vs. 0.267
±0.028, p=0.002; l: 0.481±0.052 vs.0.442±0.037, p<0.001,
respectively). For healthy subjects, the mean intra-study
changes in ECV and l between 12 and 25 minutes were
0.007±0.006 and 0.012±0.009, respectively. The mean
inter-study changes in ECV and l were 0.006±0.017 and
0.016±0.025, respectively. Thus, the inter-study ECV
and l variation was about 2.8 times greater than the
intra-study ECV and l variation in healthy subjects
(ECV:0.017 vs. 0.006, l:0.025 vs. 0.009, respectively). In
heart failure subjects, the intra-study differences
between 12 and 25min ECV and l were 0.007±0.017
and 0.012±0.028, respectively. The estimated sample size
to detect a one standard deviation (SD) change of ECV
(0.035) or l (0.05) with a power of 80% and an alpha
error of 0.05 for heart failure subjects using a two group
design was 31 and 40 in each group, respectively.
Conclusions
ECV and l quantification have a low variability across
scans, and could be a viable tool for evaluating clinical
trial outcome. ECV requires a smaller sample size than
l to detect group differences from treatment.
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Figure 1 Sample size required in each group to detect a certain ECV difference with a two group design of 80% power and an alpha error of
0.05. The X axis values corresponding to the ECV difference need to be detected like the first column in Table 1. The three curves
corresponding to case 1, 2 and 3 of Table 1.
Table 1 Estimated sample size in heart failure group to
detect the change of ECV and l with a power of 80%
Clinical change Case 1 Case 2 Case 3
SDD1 N1 SDD2 N2 SDD3 N3
l(0.05) 0.078 40 0.117 87 0.156 154
ECV(0.035) 0.048 31 0.072 68 0.096 120
Sample size need to detect a clinical meaning change of ECV and l with 80%
of power and an alpha error of 0.05. Sample size is derived from the inter-
study SDD. Note that for studies comparing active vs. placebo, these sample
size numbers need to be doubled. Case 1: the inter-study SDD1 in HF group
was estimated 3 fold greater than the intra-study SDD; Case 2, the inter-study
SDD2 was estimated 1.5 times more than SDD1; Case3, the inter-study SDD3
was estimated 2 times more than SDD1.
Liu et al. Journal of Cardiovascular Magnetic
Resonance 2013, 15(Suppl 1):P39
http://www.jcmr-online.com/content/15/S1/P39
Page 2 of 2
